

Summary of Changes – 8/3/26

Reblozyl SGM 3407-A 2025b – Added the member cannot take Reblozyl concomitantly with Aqvesme for the treatment of beta-thalassemia.

Inqovi SGM 4002-A 2026a – Added coverage for acute myeloid leukemia per label update.

Enhertu SGM 3470-A 2025c – Added coverage for early stage HER2-positive breast cancer per label update.

Fertility Preservation REG 6956-A 04-2026 v2 – Added the state of California per California Senate Bill 729.

Vfend, voriconazole PA 241-A 01-2026 v2 – Added newly FDA approved voriconazole injection to target drug list. Updated document title.

Imfinzi SGM 1820-A 2026c – Added coverage for non-muscle invasive bladder cancer per label update.

Neulasta and pegfilgrastim biosimilars SGM 1931-A 2025b – Added Ennumo (pegfilgrastim-pccg) to the criteria, per FDA approval.

Cosentyx SGM 2017-A 2026a – For ankylosing spondylitis, updated criteria to include pediatric patients 12 years of age and older per FDA label age expansion.

Kresladi SGM 7460-A 2026 – Asking for member is 9 months to less than 10 years, diagnosis of severe leukocyte adhesion deficiency-I (LAD-I) confirmed by genetic testing, flow cytometry within certain levels, appropriate candidate for HSCT, no active comorbidity concerns such as infection or other significant medical conditions, and has not received Kresladi or any other gene therapy previously.

Lynavoy SGM 7424-A 2026 – Asking for diagnosis of cholestatic pruritus in primary biliary cholangitis (PBC) is confirmed by labs and does not have any other concomitant liver disease. Continuation of care when experiencing positive benefit.

Otarmeni SGM 7475-A 2026 – Member is 17 years of age or younger, biallelic, likely pathogenic, or pathogenic OTOF variants, profound sensorineural hearing loss, outer hair cell presence, no evidence hearing loss is dependent on body temperature, does not have surgical anatomy that would preclude this approach, no history of untreatable hearing loss conditions, cochlear implants in the ears, malignancies, or meningitis, and member has not received this drug or other gene therapy previously.

Icotyde SGM 7418-A 2026 – Diagnosis of plaque psoriasis, 12 years of age or older, and one of the following: high impact sites, at least 10% of body surface area affected, at least

3% of body surface area affected and has tried and failed phototherapy or treatment with methotrexate, cyclosporine, or acitretin. Reauthorization with positive response in reduction in body surface area from baseline or improvement in signs and symptoms.